Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
|ClinicalTrials.gov Identifier: NCT00684476|
Recruitment Status : Completed
First Posted : May 26, 2008
Last Update Posted : May 26, 2008
|Condition or disease||Intervention/treatment||Phase|
|Venom Allergy||Drug: venom immunotherapy||Phase 4|
Background: The intervals at which maintenance venom immunotherapy (MVIT) is administered have been progressively extended over the years.
Objective: To examine whether the administration of bee venom (BV) maintenance dose (MD) at 6-month interval is safe and efficacious.
Methods: The usual 3-month interval at which venom allergic patients were receiving their MVIT was gradually extended to 6 months. Systemic reactions (SRs) to immunotherapy injections or to field stings were regularly recorded. BV allergic patients were deliberately sting-challenged after reaching the 6-month interval.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||June 2004|
|Estimated Study Completion Date :||May 2006|
- whether the administration of bee venom (BV)
- maintenance dose (MD) at 6-month interval is safe and
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00684476
|Principal Investigator:||Arnon Goldberg, M.D||The Allergy and Clinical Immunology Unit, Meir Hospital, Kfar-Saba, Israel, affiliated with The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel|